MRNA · News · 20260802N

Market Demand Trends

Moderna, Inc. · 2026-08-02 · Importance 20 · Surprise 24

Moderna continues to face weak demand for its COVID-19 vaccines as pandemic-era sales decline. COVID vaccine sales remain a significant influence on the company’s top line, creating pressure as Moderna transitions toward a broader vaccine and therapeutics portfolio. The company is seeking to offset the decline with its seasonal flu vaccine and a future COVID-flu combination product.

Key facts

• MarketBeat reported The Manufacturers Life Insurance Company reduced its stake in Moderna by 29.7% in Q1 2026, selling 132,808 shares and retaining 314,872 shares valued at $16.0 million. source